• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Osteopenia - Pipeline Review, Q4 2010 - Product Image

Osteopenia - Pipeline Review, Q4 2010

  • Published: December 2010
  • 36 pages
  • Global Markets Direct

Osteopenia - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Osteopenia Pipeline Review, Q4 2010”, provides an overview of the Osteopenia therapeutic pipeline. This report provides information on the therapeutic development for Osteopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteopenia. “Osteopenia-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Osteopenia.
- A review of the Osteopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteopenia Overview
Therapeutics Development
An Overview of Pipeline Products for Osteopenia
Osteopenia Therapeutics under Development by Companies
Osteopenia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Osteopenia Therapeutics Development
Amgen Inc.
Ono Pharmaceutical Co., Ltd.
Universities/Institutes Involved in Osteopenia Therapeutics Development
Osteopenia Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Prolia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Genistein - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nitroglycerin Ointment - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zoledronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Osteopenia - Featured News
Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-111 In Patients With Tibial Plateau Fractures
Sep 19, 2007: Increased Bone Mineral Density Seen In Phase IIB Study With Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor.
Sep 22, 2003: Emisphere Announces Oral Salmon Calcitonin (SMC021) Phase IIa Data Are Presented By Novartis At The American Society For Bone And Mineral Research Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos